2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Bio Green Med Solution reported second quarter 2026 results on August 12, 2026, with $336,000 in fire safety product revenue and a net loss of $0.4 million, compared with a $1.3 million net loss a year earlier. The company also disclosed a June 2026 Business Combination Agreement under which Future NRG Sdn. Bhd. shareholders would receive more than 99% of the combined company, which would matter to shareholders if the exchange closes.
Revenue of $336,000 for the quarter ended June 30, 2026, versus no revenue in the prior-year period, following the September 2025 acquisition of Fitters Sdn. Bhd.
Net loss of $0.4 million, or $(0.08) per share from continuing operations, compared with $1.3 million, or $(0.93) per share, a year earlier.
June 2026 Business Combination Agreement with Future NRG Sdn. Bhd.; the Exchange can be terminated by either party if not closed by December 31, 2026.
Cash and cash equivalents of $3.8 million as of June 30, 2026; the company estimates current resources will fund planned expenditure into the first quarter of 2027.
Creative Media & Community Trust Corporation (CMCT) reported a second-quarter 2026 net loss attributable to common stockholders of $11.0 million, or $4.03 per diluted share, compared with $14.3 million a year earlier. Total revenues were $29.7 million, roughly flat year over year, while total segment net operating income fell 5.2% to $9.3 million. The company also said it elected not to invest the capital needed to refinance the Oakland Office Building mortgage, which had an outstanding balance of $97.1 million and matured in the third quarter of 2026.
Net loss attributable to common stockholders was $11.0 million for the quarter ended June 30, 2026, versus $14.3 million in the same period of 2025.
FFO was $(3.5) million and Core FFO was $(3.4) million, compared with $(7.9) million and $(7.0) million a year earlier.
Total segment NOI decreased 5.2% to $9.3 million, while NOI excluding loss from unconsolidated entities rose 22.2% to $12.5 million.
The $97.1 million non-recourse mortgage on the Oakland Office Building matured in the third quarter of 2026; the company continues to engage with the servicer on a long-term resolution.
BK Technologies Corporation announced its financial and operating results for the quarter ended June 30, 2026, on August 13, 2026, through an amended press release and an earnings presentation. The filing does not state revenue, profit, or guidance figures, so the results' direction cannot be judged from this document alone.
Results cover the second quarter ended June 30, 2026, announced August 13, 2026.
The amended press release is furnished as Exhibit 99.1.
The earnings presentation is furnished as Exhibit 99.2 and is posted at www.bktechnologies.com.
The filing is signed by CFO Scott A. Malmanger, dated August 13, 2026.
Binah Capital Group reported second-quarter 2026 results, with total revenue of $46.5 million, up 12.1% from $41.5 million a year earlier, and GAAP net income of $0.3 million, compared with a net loss of $0.7 million in the prior-year quarter. Assets under management reached $31.6 billion, up 13.4% year over year, and the filing gives no guidance for future periods, so shareholders can weigh these figures against the company's continued growth in its advisory and brokerage business.
Total revenue of $46.5 million for the quarter ended June 30, 2026, up 12.1% from $41.5 million
GAAP net income of $0.3 million versus a net loss of $0.7 million a year earlier; diluted EPS was $(0.00) versus $(0.06)
Assets under management of $31.6 billion, up 13.4% from $27.8 billion; adjusted EBITDA of $1.2 million, up 21%
Cash and equivalents of $10.5 million and long-term debt of $17.3 million as of June 30, 2026
Idaho Strategic Resources reported second-quarter 2026 revenue of $10,732,335, up 13.25% from a year earlier, with net income attributable to the company up 31.95% to $3,651,596. The company said a wildfire halted milling at its New Jersey mill for about a week in June and that a change in mining method and grade variations affected the quarter, and all-in sustaining cost per ounce rose 16.08% to $2,261.81.
Revenue was $10,732,335 for Q2 2026, up 13.25% from $9,476,739 in Q2 2025.
Net income attributable to IDR was $3,651,596, up 31.95%; EPS was $0.23 versus $0.20.
Average flotation feed grade fell 20.86% to 7.89 gpt; ounces produced rose 1.23% to 3,047.
All-in sustaining cost per ounce rose 16.08% to $2,261.81; average realized gold price was $4,277.53, up 32.70%.
Presidio Production Company reported second-quarter 2026 total revenue of $54.0 million and net income attributable to the company of $14.4 million, or $0.34 per Class A share. The filing presents no prior-period comparison, so the direction of change versus last year or last quarter cannot be determined from it. The company also declared a quarterly dividend of $0.3375 per share and disclosed the July 2026 closing of the Canyon Creek acquisition.
Total revenue was $54.0 million and Adjusted EBITDA was $33.2 million for the quarter ended June 30, 2026.
Quarterly dividend of $0.3375 per share is payable September 14, 2026 to holders of record as of August 31, 2026.
Canyon Creek acquisition closed July 1, 2026, funded with a $55 million draw under the ABS Warehouse Facility and 1,962,240 Class A shares issued to sellers.
AirJoule Technologies reported a second-quarter 2026 net loss of $8.5 million, or $0.12 per share, compared with net income of $2.5 million, or $0.04 per share, a year earlier. The company also raised its expected 2026 combined cash spend to $27 million to $28 million, up from about $25 million previously, and signed an exclusive sales agreement with Kubota Corporation. Shareholders face a wider loss and higher planned spending, while the company reports $41.4 million of cash and no debt.
Q2 2026 net loss of $8.5 million, or $0.12 per share, versus net income of $2.5 million, or $0.04 per share, in Q2 2025.
Six-month net loss of $58.4 million, or $0.85 per share, includes a $65.7 million equity loss from the investment in AirJoule, LLC.
2026 combined cash spend now expected at $27 million to $28 million, up from about $25 million previously.
Cash of $41.4 million at June 30, 2026; Kubota agreement covers deployments in Texas and California beginning in Q3 2026.
Interlink Electronics reported results for the quarter ended June 30, 2026. Revenue rose 10% to $3.77 million, and net income was $248,000, compared with $100,000 a year earlier. The company also said it is exploring debt financing for a pending acquisition it expects to complete by the end of October 2026.
Q2 2026 revenue was $3.77 million, up 10.4% from $3.41 million in Q2 2025
Q2 2026 net income was $248,000 versus $100,000 a year earlier; first-half net loss narrowed to $90,000 from $705,000
Q2 2026 gross margin was 44.4%, down from 45.0%; first-half gross margin rose to 44.0% from 40.9%
Acquisition announced in May 2026 is expected to close by the end of October 2026; company is exploring debt financing options
REalloys reported second-quarter 2026 net revenues of $0.8 million, up from $0.4 million a year earlier, but its net loss widened to $36.8 million, or $0.59 per diluted share, from $2.2 million, or $0.05 per share. The company said the increase was driven mainly by $32.1 million of non-cash stock-based compensation, and it ended the quarter with $122.4 million in cash, which it says covers its committed strategic project funding without additional financing.
Net revenues were $0.8 million for the quarter ended June 30, 2026, compared with $0.4 million a year earlier.
Net loss was $36.8 million, or $0.59 per diluted share, versus $2.2 million, or $0.05 per share, in the prior-year quarter.
Non-cash stock-based compensation of $32.1 million was the main driver of the higher loss.
Cash was $122.4 million at June 30, 2026, after a $100.0 million private placement closed in June 2026; Craig Cunningham became Chief Financial Officer effective June 24, 2026.
Dawson Geophysical reported unaudited second-quarter 2026 revenue of $17.9 million, up 82% from a year earlier, but a net loss of $3.4 million, or $0.11 per share, which was wider than the $2.3 million loss in the second quarter of 2025. The loss included $1.7 million of strategic transaction costs tied to discussions with controlling stockholder Wilks Brothers, LLC, which the filing says controls about 80% of the common stock. There is no guarantee a definitive agreement will be reached, and a special committee of independent directors is evaluating any such transaction.
Second-quarter fee revenue was $14.0 million, up 60%; total revenue was $17.9 million, up 82% from $9.9 million.
Second-quarter net loss was $3.4 million, or $0.11 per share, including $1.7 million of strategic transaction costs; Adjusted EBITDA was $0.6 million versus negative $1.2 million a year earlier.
Six-month net income was $4.2 million, or $0.14 per share, including $2.4 million of strategic transaction costs.
Discussions with Wilks Brothers, LLC and its affiliates on possible transactions are ongoing; no definitive agreement has been reached.
Lument Finance Trust reported a GAAP net loss attributable to common shareholders of $9.2 million, or $0.18 per share, for the quarter ended June 30, 2026, and a Distributable Loss of $5.3 million, or $0.10 per share. The board also approved a 1-for-10 reverse stock split, which the company says is intended to regain compliance with New York Stock Exchange listing requirements; for shareholders, the number of shares falls from about 52.5 million to about 5.3 million while ownership percentages are unchanged apart from cash paid for fractional shares.
Q2 2026 GAAP net loss attributable to common shareholders of $9.2 million, or $0.18 per share
Q2 2026 Distributable Loss of $5.3 million, or $0.10 per share, versus Distributable Earnings of $0.02 per share in Q1 2026
Reverse split expected to take effect at 5:00 pm ET on September 9, 2026, with split-adjusted trading beginning September 10, 2026 under ticker LFT
Book value per share of common stock was $2.76 as of June 30, 2026, down from $2.97 in the prior quarter; a $0.04 per share common dividend was declared
Instil Bio reported a second-quarter 2026 net loss of $4.3 million, or $0.63 per share, down from $21.4 million, or $3.24 per share, a year earlier. The company had $69.9 million in cash and marketable securities at June 30, 2026, down from $76.3 million at December 31, 2025, and expects that balance to fund its operating plan beyond 2027. Shareholders are seeing a much smaller loss, but the company is also evaluating acquisitions and in-licensing deals that could change its spending.
Q2 2026 net loss was $4.3 million ($0.63 per share), versus $21.4 million ($3.24 per share) in Q2 2025.
In-process R&D expense was nil in Q2 2026, compared with $10.0 million in Q2 2025.
Cash, cash equivalents, restricted cash and marketable securities were $69.9 million at June 30, 2026, versus $76.3 million at December 31, 2025.
Instil is evaluating potential acquisitions, in-licensing and related opportunities.
Calidi Biotherapeutics reported a second-quarter 2026 net loss attributable to common stockholders of $4.2 million, or $2.94 per share, compared with $5.7 million, or $31.75 per share, a year earlier; per-share figures reflect a 1-for-16 reverse split completed in July 2026. Cash fell to $4.1 million by June 30, 2026, and the company's filing lists the risk that it may not raise sufficient capital, which matters for shareholders.
Net loss attributable to common stockholders was $4.2 million, or $2.94 per share, for Q2 2026, versus $5.7 million, or $31.75 per share, in Q2 2025.
General and administrative expenses were $1.6 million, down from $3.1 million; research and development expenses were $2.6 million, unchanged year over year.
Cash was $4.1 million at June 30, 2026, down from $5.6 million at December 31, 2025.
The FDA gave positive pre-IND feedback on CLD-401, and the company targets first patient dosing in Q1 2027.
Nuwellis reported second-quarter 2026 net sales of $2.0 million, up 14% from the prior-year quarter, and gross margin of 76% versus 56% a year earlier. The net loss narrowed to $4.8 million from $12.6 million, though it included about $1.7 million of non-cash warrant valuation expense. The company said about $12.7 million in gross proceeds from June and July financings and warrant exercises extends its cash runway through the second quarter of 2027.
Q2 net sales $2.0 million, up 14%; U.S. revenue up 17%
Q2 gross margin 76%, compared with 56% in the prior-year quarter
Q2 net loss $4.8 million, versus $12.6 million; includes about $1.7 million non-cash warrant expense
Cash of $3.9 million at June 30, 2026; about $12.7 million gross raised in June and after quarter-end
KIDZ AI Inc. reported second quarter 2026 results for the period ended June 30, 2026. Service revenue fell about 34% year over year to about $0.48 million, while the net loss narrowed 35% to about $2.50 million, and the company said the revenue decline reflects a shift of focus toward its AI infrastructure build-out, where AI compute revenue has not yet started.
Service revenue was about $0.48 million, versus about $0.73 million in the prior year period, a decrease of about 34%.
Net loss was about $2.50 million, versus about $3.87 million a year earlier; gross margin was 44%, consistent with the prior year quarter.
Cash and restricted cash were about $8.88 million at June 30, 2026, up from about $2.75 million at December 31, 2025.
Convertible notes payable fell from about $8.20 million to about $0.67 million since year-end, primarily through conversions to equity.
Gemini reported second-quarter 2026 total revenue of $45.5 million, up 37% from a year earlier, and a net loss of $107.7 million, down 19% from $133.2 million. Exchange revenue fell 38% amid a softer crypto market, while the company said its services and cost initiatives drove growth and lower expenses. Adjusted EBITDA worsened to a loss of $74.0 million, mainly due to losses on bitcoin received in a May 2026 private placement.
Total revenue was $45.5 million versus $33.3 million in Q2 2025; exchange revenue fell 38% to $12.5 million.
Net loss was $107.7 million versus $133.2 million; loss per share was $(0.89) versus $(27.08).
Adjusted EBITDA loss widened to $74.0 million from $51.9 million a year earlier.
A $16.1 million provision for credit losses on the credit card portfolio was tied to an identity fraud event; an earnings call is set for August 14, 2026 at 8:30 a.m. E.T.
XBP Global reported second quarter 2026 revenue of $191.3 million, down 14.0% year-over-year on a pro forma basis, and a net loss of $16.7 million. Normalized EBITDA rose 8.4% pro forma to $21.9 million, and the company raised its annualized operational efficiency target to $65 to $75 million from $55 to $60 million. The company also said it has engaged a financial advisor in connection with previously announced strategic alternatives.
Revenue of $191.3 million, down 14.0% year-over-year on a pro forma basis
Net loss of $16.7 million; Normalized EBITDA of $21.9 million, up 8.4% pro forma
Adjusted gross margin of 24.9%, described by the company as its highest level to date
Efficiency target raised to $65 to $75 million annualized, with approximately $35 million expected in 2026
CPI Aerostructures reported results for the quarter ended June 30, 2026, with revenue of $17.6 million, up from $15.2 million a year earlier, and net income of $0.7 million, or $0.05 per diluted share, compared with a net loss of $1.3 million in the same quarter of 2025. For the six months, revenue was $34.9 million and net income was $1.9 million, compared with a net loss of $2.6 million a year earlier, and the company cited a total backlog of $533 million.
Q2 2026 revenue of $17.6 million vs. $15.2 million in Q2 2025; gross margin of 22.0% vs. 4.4%
Q2 2026 net income of $0.7 million ($0.05 per diluted share) vs. net loss of $1.3 million ($0.10 loss per share)
Six months 2026 net income of $1.9 million vs. net loss of $2.6 million; adjusted EBITDA of $3.5 million vs. $(2.5) million
Total backlog of $533 million, including $433 million unfunded backlog of future orders
CAMP4 Therapeutics reported a second-quarter 2026 net loss of $33.5 million, up from $12.6 million a year earlier, mainly due to a $20.9 million non-cash loss from a change in fair value of a derivative tranche liability tied to its September 2025 private placement. Revenue rose to $1.8 million from $1.5 million, and the company said its cash is sufficient to fund planned activities through the end of 2028.
Net loss for the quarter ended June 30, 2026, was $33.5 million, compared with $12.6 million a year earlier.
Research and collaboration revenue was $1.8 million, up from $1.5 million; R&D expenses were $10.8 million and G&A expenses were $4.3 million.
Cash and cash equivalents were $86.4 million at June 30, 2026, down from $109.5 million at December 31, 2025; the company closed a second private placement tranche raising $50.1 million after quarter-end.
Regulatory clearance was received in Australia and Argentina for a Phase 1/2 trial of CMP-002, with trial launch expected in Q4 2026.
KinderCare reported second-quarter 2026 revenue of $697.5 million, down 0.4% from a year earlier, and a net loss of $8.8 million, compared with net income of $38.6 million in the second quarter of 2025. The company also updated its full-year 2026 guidance, but the filing does not state the prior ranges, so the direction of the change cannot be determined from this document.
Revenue of $697.5 million vs. $700.1 million in Q2 2025; center enrollment fell 4.0%
Net loss of $8.8 million, or $0.07 per diluted share, vs. net income of $38.6 million, or $0.33, a year earlier
Adjusted EBITDA of $63.0 million, down 23.6%; impairment losses rose $20.7 million and 49 centers closed in Q2
Full-year 2026 guidance: revenue $2.66 billion to $2.70 billion; adjusted EBITDA $200 million to $220 million; adjusted EPS $0.05 to $0.15
Oxbridge Re Holdings reported net income of $176,000, or $0.02 per share, for the quarter ended June 30, 2026, compared with a net loss of $1.87 million a year earlier. The company recorded no underwriting losses in the quarter, and total revenue rose to $940,000 from $664,000, helped by $501,000 of SurancePlus management fee income. The filing also announced AI GridWorks, a new subsidiary to develop, own and operate AI data centers.
Q2 2026 net income was $176,000, or $0.02 per share, versus a net loss of $1.87 million, or $0.25 per share, in Q2 2025.
Net premiums earned fell to $368,000 from $582,000, while no underwriting losses were recorded in Q2 2026 compared with a full limit loss on one reinsurance contract in Q2 2025.
Restricted cash and cash equivalents rose $12.85 million to $19.82 million as of June 30, 2026, from $6.98 million at December 31, 2025.
AI GridWorks was launched after quarter-end to develop, own and operate AI data centers; the filing does not state its funding or capital commitment.
Roadzen reported revenue of $16.2 million for the quarter ended June 30, 2026, up 49% from $10.9 million a year earlier and the highest quarterly revenue in company history. The net loss attributable to ordinary shareholders widened to $9.8 million, or $(0.12) per share, from $4.0 million, or $(0.05) per share, mainly due to a $7.2 million non-cash fair-value loss, while the Adjusted EBITDA loss narrowed to $0.37 million.
Revenue of $16.2 million, up from $10.9 million in the prior-year quarter, an increase of 49%
Net loss attributable to ordinary shareholders of $9.8 million, or $(0.12) per share, versus $4.0 million, or $(0.05) per share, a year earlier; includes a $7.2 million non-cash fair-value loss
Adjusted EBITDA loss of $0.37 million versus $1.41 million a year earlier, the eighth consecutive quarter of improvement
On July 9, 2026, the company signed a definitive agreement to acquire a European MGA with approximately $18–20 million in expected annual revenue
Xos reported second-quarter 2026 revenue of $4.7 million, down from $18.4 million a year earlier, while gross margin rose to 12.1% and net loss narrowed to $6.9 million. The company is revising its 2026 outlook, citing shifted second-half product mix and volume, and says second-quarter deliveries moved into later quarters.
Q2 2026 revenue was $4.7 million on 30 units, versus $18.4 million on 135 units in Q2 2025
Q2 2026 net loss was $6.9 million, compared with $7.5 million in Q2 2025; GAAP operating loss widened to $7.9 million from $7.1 million
Revised 2026 outlook: revenue of $35 to $43 million, non-GAAP operating loss of $(14.7) million to $(11.4) million, and 250 to 350 unit deliveries
Cash and cash equivalents were $13.2 million at June 30, 2026, up from $9.8 million at March 31, 2026
Veritone reported second-quarter 2026 revenue of $24.3 million, up 4.6% from a year earlier, while its operating loss widened 16.4% to $22.1 million, including $4.5 million in restructuring expenses. Net loss narrowed to $22.2 million, mainly due to lower interest expense, and the company is targeting $3.5 million to $8.5 million in additional cost reductions by year-end 2026. For shareholders, revenue and full-year guidance point up, but gross margin fell and the operating loss grew.
Q2 2026 revenue was $24.3 million, up $1.1 million from Q2 2025; Annual Recurring Revenue was $62.0 million, up 0.2%.
Operating loss was $22.1 million versus $19.0 million a year earlier; net loss was $22.2 million versus $26.5 million, helped by $3.2 million lower interest expense.
GAAP gross margin fell to 58.5% from 67.5%, and total Software Products & Services customers declined 7.7% to 2,829.
Full-year 2026 outlook: revenue of $100 million to $115 million versus $92.6 million in fiscal 2025; non-GAAP net loss of $22.0 million to $32.0 million versus $40.8 million.
KULR Technology Group reported second quarter 2026 results that worsened on the headline measures: revenue fell 43% year over year and the company posted a net loss of $21,970,816, compared with net income a year earlier. The company attributed the loss mainly to a $10,591,667 fair value loss on its bitcoin holdings and said it has since exited Bitcoin mining and repaid its Coinbase loan in full.
Revenue decreased 43% to $2,080,177 in the quarter ended June 30, 2026, from $3,652,471 a year earlier.
Net loss was $21,970,816, or $0.47 per share, versus net income of $8,142,149, or $0.22 per share, a year earlier.
Loss from operations rose 19% to $11,204,578; gross margin was (31)% versus 20% a year earlier.
Cash balance was $12.8 million as of June 30, 2026; the company says it did not issue any shares through its ATM in the first half of 2026.
NextPlat reported second-quarter 2026 revenue of $11.9 million, down from $13.2 million a year earlier but up 21% from the first quarter. The net loss narrowed to $144,000, or $0.05 per diluted share, from $1.8 million, or $0.69 per share, in the prior-year quarter. The company's gross margin of about 40% was a record, but the filing gives no revenue or earnings guidance figures.
Revenue was $11.9 million, down from $13.2 million a year earlier and up about 21% from $9.9 million in the first quarter of 2026.
Gross margin was about 40%, a record, compared with 22% in the second quarter of 2025.
Net loss attributable to common stockholders was $144,000, or $0.05 per diluted share, versus $1.8 million, or $0.69 per share, a year earlier; the company cites about $0.5 million in one-time professional fees.
Cash was $11.9 million at June 30, 2026, with no material unsecured debt; the company also announced an intended acquisition of a pharmacy operation in the Pensacola area.
QXO reported second-quarter 2026 results for the three months ended June 30, 2026. Net sales rose to $3,246 million from $1,906 million a year earlier, and the company said the increase includes $595 million attributable to the Kodiak business acquired April 1, 2026, but GAAP net loss was $55 million versus $59 million, while Adjusted Diluted EPS fell to $0.08 from $0.11.
Net sales were $3,246 million for the quarter, up from $1,906 million, including $595 million from Kodiak.
Basic and diluted loss per share was $(0.14), compared with $(0.15) a year earlier.
Adjusted EBITDA was $272 million, up from $204 million, and Adjusted Diluted EPS was $0.08, down from $0.11.
The TopBuild acquisition was completed on July 1, 2026, after the quarter ended.
AmpliTech Group reported unaudited second-quarter 2026 revenue of $8.07 million, up about 50.9% from $5.35 million in the first quarter, and gross profit of $2.25 million, up 161.2% year over year. The net loss widened to $3.09 million from $1.77 million a year earlier as research and development and selling, general and administrative spending increased. Shareholders also saw the July 22, 2026 close of the Series A Rights process, which brought approximately $20.12 million in net proceeds.
Q2 2026 revenue was $8.07 million, versus $5.35 million in Q1 2026.
Gross margin was 27.9%, compared with 48.0% in Q1 2026 and 7.8% in Q2 2025.
Net loss was $3.09 million, versus $1.77 million in Q2 2025; R&D expense was $1.37 million.
Series A Rights closed July 22, 2026, with approximately $21.92 million gross and $20.12 million net proceeds.
Elutia reported second quarter 2026 results with net sales down to $2.4 million from $2.7 million, while its net loss narrowed to $7.6 million from $9.6 million. The company said it has secured up to $26 million in additional capital to fund NXT-41x through anticipated FDA clearance and its first full year of commercial launch, without an equity offering, which matters to shareholders because it reduces near-term dilution risk.
Q2 2026 net sales were $2.4 million versus $2.7 million a year earlier, due mainly to a $0.7 million reduction in SimpliDerm revenue from a contract manufacturer production disruption.
Adjusted EBITDA was a loss of $4.6 million versus a loss of $3.0 million in the prior-year quarter.
Up to $26 million of capital includes a $15 million credit facility ($10 million funded at closing) and up to $11 million from the SimpliDerm divestiture.
Cash and cash equivalents were $19.9 million at June 30, 2026, and the company expects the full $8 million BioEnvelope escrow to be released in the fourth quarter of 2026.
Fortress Biotech reported second quarter 2026 net revenue of $18.7 million, up 14% from $16.4 million a year earlier, and a net loss attributable to common stockholders of $2.5 million, or $0.08 per share, compared with net income of $13.4 million, or $0.50 per share basic, in the second quarter of 2025. Operating expenses fell sharply, with research and development at $0.8 million versus $8.1 million and selling, general and administrative costs at $20.8 million versus $38.8 million, and cash and cash equivalents rose to $196.6 million as of June 30, 2026 from $79.4 million at December 31, 2025.
Net revenue was $18.7 million for the quarter, of which $17.8 million came from marketed dermatology products, compared with $16.4 million a year earlier.
Loss from operations narrowed to $10.0 million from $36.5 million, driven mainly by lower SG&A and R&D expenses.
Net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, versus net income of $13.4 million, or $0.50 per share basic, in the prior-year quarter.
Partner Crystalys Therapeutics announced a $130 million Series B financing in July 2026 for dotinurad, on which subsidiary Urica is entitled to a 3% royalty on future net sales.
Cineverse reported results for the fiscal first quarter ended June 30, 2026. Revenue rose 175% to $30.6 million, mainly from the Giant Worldwide and IndiCue acquisitions, but the net loss attributable to common stockholders widened to $5.8 million, or $0.28 per share, from $3.6 million, or $0.21 per share, a year earlier. The company reaffirmed its full fiscal 2027 guidance of $115 to $120 million in revenue and $10 to $20 million in Adjusted EBITDA.
Revenue was $30.6 million versus $11.1 million in the prior-year quarter, a 175% increase.
Net loss attributable to common stockholders was $(5.8) million, or $(0.28) per share, versus $(3.6) million, or $(0.21) per share.
Adjusted EBITDA was $0.5 million, an increase of $2.6 million over the prior year.
Full fiscal 2027 guidance was reaffirmed at $115 to $120 million in revenues and $10 to $20 million in Adjusted EBITDA.
Cibus reported second-quarter 2026 results, with revenue of $994,000 versus $933,000 a year earlier and a net loss of $22.1 million versus $26.6 million. Loss per Class A share was $0.29 compared with $0.61, and the company said it expects cash to fund planned operations into early in the first quarter of 2027. Shareholders get a smaller loss and higher revenue, but cash of $20.4 million remains limited and the company may pursue financing.
Q2 2026 revenue was $994,000 versus $933,000 in Q2 2025; net loss was $22.1 million versus $26.6 million.
Net loss per Class A share was $0.29 versus $0.61 a year earlier, which the company attributed mainly to cost reduction initiatives and higher weighted average shares.
Cash and cash equivalents were $20.4 million as of June 30, 2026; the company expects this to fund operations into early Q1 2027 before any potential financing.
The company expects an annual net cash usage run-rate of about $35 million exiting 2026. Craig Wichner was appointed CEO effective June 8, 2026.
Sensus Healthcare reported second-quarter 2026 revenue of $2.3 million, down $5.0 million from the prior-year quarter, and a net loss of $8.7 million, or $0.53 per share. The company said a sale of eight units was not recorded in Q2 because of financing approval timing and will be recognized in Q3, while a $5.7 million tax expense that includes a valuation allowance against deferred tax assets added to the loss.
Q2 2026 revenue was $2.3 million versus $7.3 million in Q2 2025, with 11 units sold compared with 19 a year earlier.
Net loss was $8.7 million, or $0.53 per share, compared with a net loss of $1.0 million, or $0.06 per share, in Q2 2025.
Adjusted EBITDA, a non-GAAP measure, was negative $3.0 million versus negative $1.8 million a year earlier.
Cash, restricted cash and cash equivalents fell to $15.2 million at June 30, 2026, from $18.3 million at March 31, 2026.
Dillard's reported net income of $97.7 million, or $6.25 per share, for the 13 weeks ended August 1, 2026, up from $72.8 million, or $4.66 per share, a year earlier. The results include $37.2 million in IEEPA tariff refunds, and total retail sales rose 1%, so both sales and profit improved for shareholders.
Net income was $97.7 million, or $6.25 per share, versus $72.8 million, or $4.66 per share, in the prior-year second quarter.
Total retail sales rose 1% to $1.455 billion, and comparable store sales also rose 1%.
Net income includes $37.2 million in IEEPA tariff refunds ($1.82 per share after tax); the company does not expect additional significant refunds.
Retail gross margin was 40.9% of sales, compared with 38.1% a year earlier; operating expenses rose to $443.6 million from $434.2 million.
Trust Stamp reported results for the six months ended June 30, 2026, with net recognized revenue up 22% to $1.66 million. The net loss rose 27.29% to $4.93 million, and total operating expenses increased to $6.32 million, so higher revenue came with a larger loss for shareholders.
Net recognized revenue for the six months ended June 30, 2026 was $1.66 million, up 22% from $1.36 million, driven mainly by the S&P 500 bank customer and $192 thousand billed in Q2 for telecom work.
Net loss was $4.93 million versus $3.87 million a year earlier; basic and diluted loss per share was $0.90 compared with $1.57.
Total operating expenses were $6.32 million versus $5.20 million, including $1.42 million of non-cash expenses; cash and cash equivalents were $6.31 million at June 30, 2026.
Negotiations continue with a second African telecoms company and on three government-related contracts in Ghana, which the company expects to result in one or more definitive agreements during FY 2026.
Assembly Biosciences reported second quarter 2026 results, with collaboration revenue from Gilead rising to $13.4 million from $9.6 million and net loss falling to $3.9 million, or $0.20 per share, from $10.2 million, or $1.33 per share. The company completed $115 million in gross financing and said its cash position is projected to fund operations into 2029, which supports its pipeline programs.
Collaboration revenue was $13.4 million for the quarter ended June 30, 2026, compared with $9.6 million a year earlier, including a $5.1 million cumulative catch-up adjustment.
Net loss attributable to common stockholders was $3.9 million, or $0.20 per share, versus $10.2 million, or $1.33 per share, in the same period of 2025.
Cash, cash equivalents and marketable securities were $320.4 million at June 30, 2026, up from $226.6 million at March 31, 2026.
Completed $115 million gross financing; GS-1179 is expected to start a Phase 2 trial by year-end 2026.
Rani Therapeutics reported second-quarter 2026 results with contract revenue of $1.7 million, up from none a year earlier, and a net loss of $8.4 million, down from $11.2 million. Cash and marketable securities rose to $53.4 million, which the company says will fund operations at least through 2027, though the net loss attributable to Rani shareholders increased to $7.4 million from $6.7 million.
Q2 2026 contract revenue was $1.7 million, compared with no contract revenue in Q2 2025, primarily from the Chugai collaboration.
Net loss per Class A share attributable to Rani was $(0.04) for Q2 2026, compared with $(0.18) for Q2 2025.
Cash, cash equivalents and marketable securities totaled $53.4 million at June 30, 2026, up from $43.4 million at March 31, 2026, after a $20.0 million registered direct offering in May 2026.
Invivyd reported second-quarter 2026 PEMGARDA net product revenue of $14.3 million, up 21% from $11.8 million a year earlier. Net loss grew to $44.4 million, or $0.14 per share, from $14.7 million, or $0.12 per share, as R&D and SG&A expenses rose sharply for the VYD2311 clinical trials and commercial activities, which matters to shareholders because the company's cash of $160.1 million is expected to fund operations through the DECLARATION pivotal data readout.
Q2 2026 R&D expenses were $29.4 million, up from $9.6 million, mainly from DECLARATION and LIBERTY trial costs.
Q2 2026 SG&A expenses were $29.5 million, up from $16.6 million.
Cash and cash equivalents were $160.1 million as of June 30, 2026.
In July 2026, Invivyd received twelve months' advance notice of the termination of the PEMGARDA emergency use authorization.
Laird Superfood reported second quarter 2026 net sales of $41.3 million, up 244% from $12.0 million a year earlier, driven largely by the Navitas and Terrasoul acquisitions. The company's net loss widened to $1.8 million, or $0.25 per share, from $0.4 million, or $0.03 per share, mainly due to acquisition and integration costs; the company reaffirmed its full-year 2026 guidance.
Q2 net sales $41.3 million vs. $12.0 million in the prior-year quarter; gross margin 30.3% vs. 39.9%
Net loss $1.8 million, or $0.25 per share, vs. $0.4 million, or $0.03 per share; adjusted EBITDA $3.0 million vs. $0.1 million
Full-year 2026 guidance reaffirmed: net sales of $138 to $148 million and adjusted EBITDA of $8 to $12 million
Cash totaled $23.2 million at June 30, 2026, with no outstanding debt
Equillium reported a second-quarter 2026 net loss of $4.7 million, or $(0.04) per share, compared with $5.7 million, or $(0.16) per share, a year earlier. The company said its $57.2 million in cash is expected to fund planned operations into 2029, and it reiterated that a Phase 1 study of EQ504 is expected to begin in the fourth quarter of 2026.
Net loss for Q2 2026 was $4.7 million, or $(0.04) per basic and diluted share, versus $5.7 million, or $(0.16) per share, in Q2 2025.
R&D expenses were $2.8 million, down from $4.1 million a year earlier; G&A expenses were $2.4 million, up from $2.1 million.
Cash and cash equivalents were $57.2 million as of June 30, 2026, down from $61.3 million as of March 31, 2026.
Weighted-average shares outstanding were 111,805,635 in Q2 2026, compared with 35,719,317 in Q2 2025.
Inhibrx reported second-quarter 2026 results showing a net loss of $36.7 million, or $2.34 per share, compared with $28.7 million, or $1.85 per share, a year earlier. The company recognized no revenue in the quarter, down from $1.3 million in the second quarter of 2025, and higher interest expense on its loan contributed to the larger loss.
Net loss of $36.7 million ($2.34 per share) vs. $28.7 million ($1.85 per share) in Q2 2025
No revenue in Q2 2026 vs. $1.3 million in Q2 2025 from the Scithera license transfer
R&D expense rose to $23.9 million from $22.3 million; G&A rose to $8.3 million from $6.4 million
Cash was $133.3 million at June 30, 2026, and $219.5 million as of August 6, 2026, after $100.0 million was funded under the Oxford loan amendment on July 15, 2026
Arcadia Biosciences reported second-quarter 2026 revenue of $1.4 million, down 1% from a year earlier, and a net loss attributable to common stockholders of $6.3 million, up from $4.5 million. The company attributed the revenue shortfall to low inventory and longer-than-expected shipping times, and the larger loss to non-operating items including a $5.4 million valuation loss on its June 2026 private placement and a $2.8 million unrealized loss on its Above Food stock.
Q2 2026 total revenues were $1.443 million versus $1.455 million in Q2 2025.
Q2 2026 net loss per share was $2.09, compared with $3.26 in Q2 2025.
The company raised $4 million in gross proceeds through a June 2026 private placement and reported $4.2 million in cash at June 30, 2026.
Intellicheck reported second-quarter 2026 revenue of $5.9 million, up 16% from a year earlier, and net income of $0.7 million, compared with a net loss of $0.3 million in the same quarter of 2025. The company also disclosed that a customer representing about 29% of first-half 2026 revenue is moving to a multi-source vendor setup and testing an alternative, which it expects to reduce transaction levels with that customer.
Q2 2026 revenue was $5.9 million, up 16% year over year and up 7% sequentially.
Net income was $0.7 million, or $0.03 per diluted share, versus a net loss of $0.3 million a year earlier; adjusted EBITDA was $1.1 million versus $0.1 million.
A customer that was about 29% of first-half 2026 revenue is shifting to a multi-source architecture; the main phase was scheduled to start in late July, and the company had not yet seen the planned volume reductions as of August 12, 2026.
The company had $11.8 million in cash and no debt at June 30, 2026.
Merlin reported second quarter 2026 revenue of $2.2 million and a GAAP net loss of $58.4 million, compared with $1.0 million of revenue and a $90.4 million net loss in the first quarter. Year over year, revenue fell from $3.1 million and the net loss widened from $16.3 million, and the Adjusted EBITDA loss grew sequentially to $27.8 million from $23.3 million. Cash, cash equivalents, and short-term investments rose to $183.9 million with no debt, and the net loss attributable to common stockholders was $127.5 million after preferred stock charges.
Q2 2026 revenue was $2.2 million, up from $1.0 million in Q1 2026 and down from $3.1 million in Q2 2025.
GAAP net loss was $58.4 million, versus $90.4 million in Q1 2026 and $16.3 million in Q2 2025.
Adjusted EBITDA loss was $27.8 million, versus $23.3 million in Q1 2026.
Cash, cash equivalents, and short-term investments were $183.9 million at June 30, 2026, up from $123.1 million at March 31, 2026, and the company reported no debt.
Eledon Pharmaceuticals reported a second-quarter 2026 net loss of $31.6 million, or $0.27 per share, compared with $11.2 million, or $0.13 per share, a year earlier. The loss was driven largely by a $9.6 million non-cash charge from changes in warrant liabilities; excluding that item, the net loss was $22.0 million versus $23.5 million. Cash and short-term investments fell to $88.8 million, which the company expects to fund operations into the second quarter of 2027.
Q2 2026 net loss $31.6 million ($0.27 per share) vs. $11.2 million ($0.13 per share) in Q2 2025
Non-cash warrant liability loss of $9.6 million in Q2 2026 vs. a $12.3 million gain in Q2 2025
Excluding warrant items, net loss was $22.0 million vs. $23.5 million
Cash, cash equivalents and short-term investments were $88.8 million at June 30, 2026, funding operations into Q2 2027
Caribou Biosciences reported a second-quarter 2026 net loss of $24.3 million, or $0.24 per share, compared with $54.1 million, or $0.58 per share, a year earlier. The prior-year figure included $21.3 million in non-cash impairment charges, and licensing and other third-party revenue fell to $1.5 million from $2.7 million. The company now expects its cash to fund its current operating plan to the end of 2027, but cash, cash equivalents, and marketable securities declined to $113.8 million as of June 30, 2026, and the company said it is exploring options to fully fund its planned ANTLER-3 trial.
Net loss of $24.3 million, or $0.24 per share, for the quarter ended June 30, 2026, versus $54.1 million, or $0.58 per share, a year earlier
Licensing and other third-party revenue of $1.5 million, down from $2.7 million in the same period of 2025
Cash, cash equivalents, and marketable securities of $113.8 million at June 30, 2026, down from $142.8 million at December 31, 2025
Cash now expected to fund the current operating plan to the end of 2027; the company is exploring multiple options to fully fund the ANTLER-3 trial
MacroGenics reported second-quarter 2026 revenue of $32.8 million, up from $6.9 million a year earlier, and net income of $19.5 million, compared with a net loss of $36.3 million. The profit reflects $89.2 million of income from discontinued operations tied to the sale of its manufacturing operations, while the loss from continuing operations widened to $69.6 million, including a $52.8 million non-cash loss on extinguishing a royalty monetization liability.
Q2 2026 total revenue was $32.8 million, versus $6.9 million in Q2 2025, driven mainly by a $24.5 million Sanofi regulatory milestone.
Net income was $19.5 million, or $0.31 per share, versus a net loss of $36.3 million, or $0.57 per share, a year earlier.
Loss from continuing operations was $69.6 million, compared with $42.7 million a year earlier, after a $52.8 million non-cash loss on extinguishment of the ZYNYZ royalty monetization liability.
Pro forma cash, cash equivalents and marketable securities were $327 million, and the company guides cash runway through 2028.
ImmuCell reported unaudited results for the quarter ended June 30, 2026, with product sales up 11.5% to $7.2 million and net income of $1.8 million, or $0.20 per diluted share, versus $0.5 million, or $0.06 per basic share, a year earlier. Gross margin fell to 33.9% from 43.7%, and net income includes a one-time $2 million settlement payment from a former contract manufacturer.
Product sales rose 11.5% to approximately $7.2 million in Q2 2026, compared with the quarter ended June 30, 2025.
Gross margin declined to 33.9% of product sales from 43.7%, which the company attributed to lower manufacturing volumes, scrap from a quality issue with a purchased material, and shifted costs from the discontinued Re-Tain program.
Adjusted EBITDA was $2.7 million, compared with $1.4 million a year earlier; cash and cash equivalents rose to $8.9 million at June 30, 2026, from $3.8 million at December 31, 2025.
The company plans a capacity expansion of about $3.5 million (freeze-drying, first phase) and about $4.5 million (colostrum liquid processing, second phase), to be financed with cash on hand and cash from operations.
Alumis reported a net loss of $142.2 million for the quarter ended June 30, 2026, compared with net income of $59.3 million a year earlier, which included a $187.9 million non-operating gain tied to its ACELYRIN merger. The company took a $41.8 million impairment on the lonigutamab program after deciding to explore strategic alternatives for it, and reaffirmed that its $502.3 million in cash and marketable securities should fund operations into the fourth quarter of 2027.
Net loss of $142.2 million for the quarter, versus net income of $59.3 million a year earlier, which included a $187.9 million ACELYRIN merger gain.
Collaboration revenue of $1.7 million, down from $2.7 million a year earlier.
$41.8 million impairment loss on the acquired IPR&D intangible asset for the lonigutamab program.
Cash, cash equivalents and marketable securities of $502.3 million as of June 30, 2026; NDA submission for envudeucitinib in psoriasis planned for Q4 2026.
Capricor reported a second-quarter 2026 net loss of $40.7 million, or $0.70 per share, up from $25.9 million, or $0.57 per share, a year earlier, with no revenue recognized. The company said its FDA Advisory Committee voted 3 in favor and 9 against on cardiomyopathy efficacy for Deramiocel, and it is still working with the FDA on the Biologics License Application.
Q2 2026 net loss of $40.7 million, or $0.70 per share, versus $25.9 million, or $0.57 per share, in Q2 2025
Cash, cash equivalents and marketable securities of $237.9 million at June 30, 2026, down from $318.1 million at December 31, 2025
On July 29, 2026, the FDA Cellular, Tissue and Gene Therapies Advisory Committee voted 3 in favor and 9 against; the vote is advisory and non-binding
NS Pharma preliminary injunction motion withdrawn; the company estimates arbitration will begin this fall
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.